Yasuda, Hiroyuki

写真a

Affiliation

School of Medicine, Department of Internal Medicine (Pulmonary Medicine) (Shinanomachi)

Position

Associate Professor

External Links
Page Top ▲

Career 【 Display / hide 】

  • 2001.04
    -
    2005.03

    慶應義塾大学医学部内科学教室

  • 2005.04
    -
    2010.12

    慶應義塾大学医学部内科学（呼吸器）

  • 2011.01
    -
    2012.03

    Beth Israel Deaconess Medical Center, Harvard Medical School

  • 2012.04
    -
    Present

    慶應義塾大学医学部内科学（呼吸器）

Page Top ▲

Academic Background 【 Display / hide 】

  • 2001

    慶応義塾大学, 医学部

    Graduated

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 医学博士, 慶應義塾大学, Dissertation

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Molecular biology (腫瘍生物学)

  • Life Science / Cell biology (細胞生物学)

  • Life Science / Respiratory medicine (肺癌)

Page Top ▲

Research Keywords 【 Display / hide 】

  • オルガノイド

  • トランスレーショナル研究

  • バイオバンク

  • 細胞生物学

  • 肺癌

display all >>

Page Top ▲
 

Papers 【 Display / hide 】

  • A 70-Year-Old Woman With Long-Term Nonresolving Pneumonia.

    Tomiyasu S, Kabata H, Emoto K, Azekawa S, Maeda C, Masai K, Yasuda H, Fukunaga K

    Chest 161 ( 4 ) e219 - e223 2022.04

    ISSN  0012-3692

  • Longitudinal Assessment of Prognostic Understanding in Patients with Advanced Lung Cancer and Its Association with Their Psychological Distress

    Arai D., Sato T., Nakachi I., Fujisawa D., Takeuchi M., Sato Y., Kawada I., Yasuda H., Ikemura S., Terai H., Nukaga S., Inoue T., Nakamura M., Oyamada Y., Terashima T., Sayama K., Saito F., Sakamaki F., Naoki K., Fukunaga K., Soejima K.

    Oncologist (Oncologist)  26 ( 12 ) e2265 - e2273 2021.12

    ISSN  10837159

    　View Summary

    Background: Accurate prognostic understanding in patients with advanced cancer is essential for shared decision making; however, patients may experience psychological burden through knowing the incurable nature of advanced cancer. It has been unclear how their prognostic understanding fluctuates and whether accurate prognostic understanding is associated with psychological distress from the time of diagnosis over time. Materials and Methods: We longitudinally investigated prognostic understanding in 225 patients with newly diagnosed advanced lung cancer at 16 hospitals in Japan until 24 months after diagnosis. We examined associated factors with being consistently accurate in prognostic understanding, especially focusing on its association with psychological well-being. Results: The proportion of patients with an inaccurate prognostic understanding remained approximately 20% over time with the presence of patients with inconsistent understanding. Patients with consistently accurate prognostic understanding showed a significantly lower Emotional Well-Being subscale score at both 3 and 6 months after diagnosis (p =.010 and p =.014, respectively). In multivariate analyses, being consistently accurate in prognostic understanding was significantly associated with female gender and higher lung cancer–specific symptom burden at 3 months (p =.008 and p =.005, respectively) and lower emotional well-being at 6 months (p =.006). Conclusion: Although substantial proportions of patients with advanced lung cancer had inaccurate prognostic understanding from the time of diagnosis over time, patients with consistently accurate prognostic understanding experienced greater psychological burden. Our findings highlight the importance of continuous psychological care and support for patients who understand their severe prognosis accurately. Implications for Practice: This study demonstrated that approximately 20% of patients with advanced lung cancer had an inaccurate understanding about their prognosis, not only at the time of diagnosis but also at the later time points. Being consistently accurate in prognostic understanding was significantly associated with elevated levels of psychological distress. Although accurate prognostic understanding is essential for decision making for treatment and advance care planning, health care providers should be aware of psychological burdens in patients that accept their severe prognosis accurately. Appropriate care and support for such patients are warranted from diagnosis over time.

  • A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer

    Yasuda H., Ichihara E., Sakakibara-Konishi J., Zenke Y., Takeuchi S., Morise M., Hotta K., Sato M., Matsumoto S., Tanimoto A., Matsuzawa R., Kiura K., Takashima Y., Yano S., Koyama J., Fukushima T., Hamamoto J., Terai H., Ikemura S., Takemura R., Goto K., Soejima K.

    Lung Cancer (Lung Cancer)  162   140 - 146 2021.12

    ISSN  01695002

    　View Summary

    Objectives: Several preclinical data proposed a potential efficacy of osimertinib, a third-generation EGFR tyrosine kinase inhibitor, for EGFR exon 20 insertion (EGFR ex20ins)-positive non-small cell lung cancer (NSCLC). However, reported case series and a retrospective study proposed controversial efficacy. The efficacy of osimertinib in EGFR ex20ins-positive NSCLC have not been well evaluated in prospective clinical trials. In this study, we performed a prospective, single-arm, multi-center, open-label, non-randomized phase I/II study to evaluate efficacy of osimertinib for EGFR ex20ins-positive NSCLC. Materials and methods: From August 2018 to January 2020, 14 NSCLC patients with EGFR ex20ins were enrolled, of whom 2 were excluded because they did not meet the inclusion criteria. Efficacy and safety of 80 mg osimertinib were evaluated. In addition, we performed a translational exploratory study to clarify the association of mutation type-specific drug sensitivity, osimertinib pharmacokinetic data, and clinical efficacy. Results: Of the evaluated patients, none experienced objective response, 7 experienced stable disease (58.3%), and 5 experienced disease progression (41.7%). The median progression free survival (PFS) was 3.8 months, and the median overall survival was 15.8 months. Interestingly, the exploratory study demonstrated statistically significant positive correlation between plasma osimertinib concentration/in vitro IC50 ratio and PFS (R = 0.9912, P = 0.0001), highlighting the mutation type-specific concentration-dependent efficacy of osimertinib for EGFR ex20ins-positive NSCLC. Conclusions: Regular dose, 80 mg/day, of osimertinib has limited clinical activity in NSCLC patients with EGFR ex20ins. The translational study proposed the potential efficacy of higher dose osimertinib in a subgroup of EGFR ex20ins-positive NSCLC.

  • Comprehensive and long-term surveys of COVID-19 sequelae in Japan, an ambidirectional multicentre cohort study: study protocol.

    Nakagawara K, Namkoong H, Terai H, Masaki K, Tanosaki T, Shimamoto K, Lee H, Tanaka H, Okamori S, Kabata H, Chubachi S, Ikemura S, Kamata H, Yasuda H, Kawada I, Ishii M, Ishibashi Y, Harada S, Fujita T, Ito D, Bun S, Tabuchi H, Kanzaki S, Shimizu E, Fukuda K, Yamagami J, Kobayashi K, Hirano T, Inoue T, Kagyo J, Shiomi T, Ohgino K, Sayama K, Otsuka K, Miyao N, Odani T, Oyamada Y, Masuzawa K, Nakayama S, Suzuki Y, Baba R, Nakachi I, Kuwahara N, Ishiguro T, Mashimo S, Minematsu N, Ueda S, Manabe T, Funatsu Y, Koh H, Yoshiyama T, Saito F, Ishioka K, Takahashi S, Nakamura M, Goto A, Harada N, Kusaka Y, Nakano Y, Nishio K, Tateno H, Edahiro R, Takeda Y, Kumanogoh A, Kodama N, Okamoto M, Umeda A, Hagimura K, Sato T, Miyazaki N, Takemura R, Sato Y, Takebayashi T, Nakahara J, Mimura M, Ogawa K, Shimmura S, Negishi K, Tsubota K, Amagai M, Goto R, Ibuka Y, Hasegawa N, Kitagawa Y, Kanai T, Fukunaga K

    BMJ open respiratory research 8 ( 1 )  2021.11

  • Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model

    Haga K., Takai-Todaka R., Matsumura Y., Song C., Takano T., Tojo T., Nagami A., Ishida Y., Masaki H., Tsuchiya M., Ebisudani T., Sugimoto S., Sato T., Yasuda H., Fukunaga K., Sawada A., Nemoto N., Murata K., Morimoto T., Katayama K.

    PLoS Pathogens (PLoS Pathogens)  17 ( 10 ) e1009542 2021.10

    ISSN  15537366

    　View Summary

    The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the disease COVID-19 can lead to serious symptoms, such as severe pneumonia, in the elderly and those with underlying medical conditions. While vaccines are now available, they do not work for everyone and therapeutic drugs are still needed, particularly for treating life-threatening conditions. Here, we showed nasal delivery of a new, unmodified camelid single-domain antibody (VHH), termed K-874A, effectively inhibited SARS-CoV-2 titers in infected lungs of Syrian hamsters without causing weight loss and cytokine induction. In vitro studies demonstrated that K-874A neutralized SARS-CoV-2 in both VeroE6/TMPRSS2 and human lung-derived alveolar organoid cells. Unlike other drug candidates, K-874A blocks viral membrane fusion rather than viral attachment. Cryo-electron microscopy revealed K-874A bound between the receptor binding domain and N-terminal domain of the virus S protein. Further, infected cells treated with K-874A produced fewer virus progeny that were less infective. We propose that direct administration of K-874A to the lung could be a new treatment for preventing the reinfection of amplified virus in COVID-19 patients.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • 酸素を用いた癌治療法の開発

    2024.06
    -
    2027.03

    挑戦的研究（開拓）, Principal investigator

  • 肺癌オルガノイドライブラリーを用いた肺癌シグナル経路異常の解明

    2021.04
    -
    2024.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

  • 肺癌オルガノイドライブラリー統合解析による癌の不均一性の解明と新規治療標的同定

    2020.04
    -
    2022.03

    日本医療研究開発機構（AMED), 次世代がん医療創生研究事業, Principal investigator

  • 肺癌オルガノイドを用いた治療後期肺癌の悪性度の本態解明

    2019.04
    -
    2022.03

    日本医療研究開発機構（AMED）, 革新的がん医療実用化研究事業, No Setting

  • 肺癌オルガノイドライブラリーを用いたprecision medicineの確立と新規治療標的の同定

    2018.11
    -
    2020.03

    日本医療研究開発機構（AMED）, 次世代がん医療創生研究事業, No Setting, No Setting

display all >>

Page Top ▲

Awards 【 Display / hide 】

  • 武田科学振興財団研究助成金（医学系研究継続助成）

    2019

    Type of Award： Other

  • 研究奨励賞　日本肺癌学会

    2018

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 武田科学振興財団研究助成金（医学系研究）

    2016

    Type of Award： Other

  • 第55回　日本呼吸器学会　学会奨励賞

    2015

  • 日本肺癌学会　若手奨励賞

    2015

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • PHARMACOLOGY

    2024

  • LECTURE SERIES, INTERNAL MEDICINE (PULMONOLOGY)

    2024

  • CLINICAL CLERKSHIP IN PULMONOLOGY

    2024

  • CLINICAL CLERKSHIP IN INTERNAL MEDICINE (PULMONOLOGY)

    2024

  • PHARMACOLOGY

    2023

display all >>

Page Top ▲
 

Memberships in Academic Societies 【 Display / hide 】

  • 日本癌治療学会, 

    2021.03
    -
    Present

  • 日本癌学会, 

    2020.10
    -
    Present

  • International Association for the Study of Lung Cancer, 

    2018.10
    -
    Present

  • 日本臨床腫瘍学会, 

    2007.04
    -
    Present

  • American Association for Cancer Research, 

    2005.10
    -
    Present

display all >>

Page Top ▲